...
首页> 外文期刊>Molecules >Synthesis, Evaluation, and Mechanism Study of New Tepotinib Derivatives as Antiproliferative Agents
【24h】

Synthesis, Evaluation, and Mechanism Study of New Tepotinib Derivatives as Antiproliferative Agents

机译:新型Tepotinib衍生物作为抗增殖剂的合成,评价和机理研究

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Inspired by the potent inhibition activity of the c-Met (mesenchymal?epithelial transition factor) inhibitor Tepotinib, a series of new Tepotinib derivatives were synthesized and evaluated for their ability to act as antiproliferative agents to find the leading compounds with good activity and limited side effects. Among them, compound 31e exhibited potent antiproliferative activity (IC50 (50% inhibitory concentration) = 0.026 μΜ) against hepatic carcinoma 97H (human liver cancer cell) cells and, importantly, had very low inhibitory activity against normal cells. A mechanism study demonstrated that 31e induced G1 phase (First growth phase or G indicating gap) arrest, inhibited the phosphorylation of c-Met and its downstream signaling component, Akt (Protein Kinase B), and also inhibited the migration of hepatic carcinoma 97H cells.
机译:受c-Met(间充质上皮转化因子)抑制剂Tepotinib的强抑制活性的启发,合成了一系列新的Tepotinib衍生物,并评估了它们作为抗增殖剂的能力,以发现活性良好且副作用有限的主要化合物效果。其中,化合物31e对肝癌97H(人肝癌细胞)细胞表现出有效的抗增殖活性(IC 50(50%抑制浓度)=0.026μM),重要的是,对正常细胞的抑制活性非常低。一项机制研究表明,31e诱导G1期(第一个生长期或G表示缺口)停滞,抑制c-Met及其下游信号传导成分Akt(蛋白激酶B)的磷酸化,还抑制肝癌97H细胞的迁移。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号